Regulatory B Cells and Chronic Immune Thrombocytopenia

NCT ID: NCT02891109

Last Updated: 2016-09-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

36 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-01-31

Study Completion Date

2015-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The chronic immune thrombopenia is an autoimmune disease caused by B cells. These cells produce anti platelets and megakaryocytes antibodies. Some B cells, named regulatory B cells, are known to control other cells. Their action in chronic immune thrombopenia is actually unknown.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The chronic immune thrombopenia is an autoimmune disease caused by B cells. These cells produce anti platelets and megakaryocytes antibodies. Some B cells, named regulatory B cells, are known to control other cells. Their action in chronic immune thrombopenia is actually unknown. In our cohort of chronic immune thrombopenia and controls, we realized a flow cytometry analyze of B and T cells and a co-culture to determine regulatory B cells functionality.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Purpura, Thrombocytopenic, Idiopathic Regulatory B Cells

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients group

Adults patients with chronic immune thrombocytopenia

Biological tests

Intervention Type BIOLOGICAL

From the blood: B and T cells extraction then co-culture B and T cells and characterization of lymphocytes by flow cytometry

control group

Adults without immune thrombocytopenia

Biological tests

Intervention Type BIOLOGICAL

From the blood: B and T cells extraction then co-culture B and T cells and characterization of lymphocytes by flow cytometry

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biological tests

From the blood: B and T cells extraction then co-culture B and T cells and characterization of lymphocytes by flow cytometry

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Purpura, Thrombocytopenic, Idiopathic, chronic phase (\>12 months)
* no treatment or thrombopoietin receptor agonists

Exclusion Criteria

* \< 18 years
* Purpura, Thrombocytopenic, Idiopathic, acute phase
* pregnancy
* others causes of thrombopenia
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Brest

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christophe Jamin, PhD

Role: PRINCIPAL_INVESTIGATOR

CHRU de Brest

Lenaig Le Clech, MD

Role: PRINCIPAL_INVESTIGATOR

CHRU Brest

Brigitte Pan-Petesh, MD

Role: PRINCIPAL_INVESTIGATOR

CHRU Brest

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHRU de Brest

Brest, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PTIREG

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Sirolimus for Autoimmune Disease of Blood Cells
NCT00392951 COMPLETED PHASE1/PHASE2
COVID-19 Vaccine Responses in PIDD Subjects
NCT05321407 ACTIVE_NOT_RECRUITING